ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cutaneous manifestations"

  • Abstract Number: 425 • 2015 ACR/ARHP Annual Meeting

    Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus

    Julie Barsalou1, Nathalie Costedoat-Chalumeau2, Cesar Fors-Nieves3, Ummara Shah4, Patrick Brown5, Carl Laskin6, Nathalie Morel2, Kateri Levesque7, Jill P. Buyon8, Earl Silverman9 and Peter M. Izmirly10, 1Pediatric Rheumatology, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, 2Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, 3Division of Rheumatology, NYU School of Medicine, New York, NY, 4Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, 5University of Toronto, Toronto, ON, Canada, 6Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, 7Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, 8NYU School of Medicine, New York, NY, 9Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 10Rheumatology, NYU School of Medicine, New York, NY

    Background/Purpose: Biopsy specimens of cutaneous neonatal lupus (cNL) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in connective…
  • Abstract Number: 1074 • 2015 ACR/ARHP Annual Meeting

    DNA Methylation Patterns in Naïve CD4+ T Cells Identify Epigenetic Susceptibility Loci for Malar Rash and Discoid Rash in Systemic Lupus Erythematosus

    Paul Renauer1, Patrick Coit1, Matlock A. Jeffries2, Joan T. Merrill3, W Joseph McCune4, Kathleen Maksimowicz-McKinnon5 and Amr H. Sawalha6, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Int Med/ Rheum, University of Michigan, Ann Arbor, MI, 5Rheumatology, Henry Ford Hospital, Detroit, MI, 6Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous clinical manifestations, autoantibody production, and epigenetic dysregulation in T cells. We sought…
  • Abstract Number: 2776 • 2014 ACR/ARHP Annual Meeting

    Drug-Associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center

    Montserrat Santos-Gómez1, Francisco Ortiz Sanjuan1, Ricardo Blanco1, Jose L. Hernández2, Vanesa Calvo-Río1, Javier Loricera1, Carmen Gonzalez-Vela3, Trinitario Pina Murcia4, Hector Fernandez-Llaca5, Susana Armesto5, Victor Martínez-Taboada1, Javier Rueda-Gotor1, Leyre Riancho-Zarrabeitia1 and Miguel A. González-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 2Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 3Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 4Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, 5Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain

    Background/Purpose The 2012 International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides defined drug-associated immune complex vasculitis as a distinct entity included within the…
  • Abstract Number: 804 • 2014 ACR/ARHP Annual Meeting

    Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature

    Alice Sy1, Natasha Dehghan2, Nader A. Khalidi3, Lillian Barra4, Simon Carette5, David Cuthbertson6, Gary S. Hoffman7, Curry L Koening8, Carol A. Langford9, Carol McAlear10, Paul A. Monach11, Larry W. Moreland12, Philip Seo13, Ulrich Specks14, Steven R. Ytterberg15, Gert Van Assche16, Peter A. Merkel10 and Christian Pagnoux5, 1Medicine Division, London, ON, Canada, 2Rheumatology Division, Vancouver, BC, Canada, 3Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, 4Rheumatology, St. Joseph's Health Care, London, ON, Canada, 5Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 6Department of Biostatistics, University of South Florida, Tampa, FL, 7Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 8Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, 9Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 10University of Pennsylvania, Philadelphia, PA, 11Rheumatology, Boston University, Boston, MA, 12Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 13Johns Hopkins Vasculitis Center, Rheumatology Division, Johns Hopkins University, Baltimore, MD, 14Mayo Clinic, Rochester, MN, 15Rheumatology Division, Mayo Clinic, Rochester, MN, 16Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose:  Small case series suggested that vasculitis and inflammatory bowel disease (IBD; Crohn’s disease [CD] or ulcerative colitis [UC]) can co-occur more commonly than the…
  • Abstract Number: 1548 • 2012 ACR/ARHP Annual Meeting

    Cutaneous Vasculitis as a Paraneoplastic Syndrome

    Javier Loricera1, Vanesa Calvo-Rio2, Francisco Ortiz Sanjuan3, Marcos Antonio Gonzalez-Lopez4, Hector Fernandez-Llaca4, Javier Rueda-Gotor2, Carmen Gonzalez-Vela5, Cristina Mata-Arnaiz3, Miguel A. Gonzalez-Gay2 and Ricardo Blanco2, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 4Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 5Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain

    Background/Purpose: Cutaneous Leukocytoclastic Vasculitis (CLV) may be associated with malignancies, and sometimes it behaves as a paraneoplastic syndrome. This association has been reported in a…
  • Abstract Number: 1507 • 2012 ACR/ARHP Annual Meeting

    Propylthiouracil Reduces Fibrosis in Chronic Oxidant Stress Mouse Model of Scleroderma

    Gianluca Bagnato1, Alessandra Bitto2, Natasha Irrera2, Gabriele Pizzino2, Neal Roberts3, Maurizio Cinquegrani4, Donatella Sangari1, Francesco Squadrito2, Gianfilippo Bagnato1 and Antonino Saitta4, 1Rheumatology, University of Messina, Messina, Italy, 2Pharmacology, University of Messina, Messina, Italy, 3Medical College of Virginia, Richmond, VA, 4Internal Medicine, University of Messina, Messina, Italy

    Background/Purpose: Systemic sclerosis (SSc) is characterized by fibrosis of skin and visceral organs; vascular damage and resultant ischemia; and immunological dysregulation manifested by autoantibodies. Hypothyroidism,…
  • Abstract Number: 1508 • 2012 ACR/ARHP Annual Meeting

    Simvastatin Attenuates Pulmonary Fibrosis in a Murine Model of Systemic Sclerosis

    Gianluca Bagnato1, Alessandra Bitto2, Natasha Irrera2, Gabriele Pizzino2, Donatella Sangari1, Maurizio Cinquegrani3, Neal Roberts4, Gianfilippo Bagnato1, Francesco Squadrito2 and Antonino Saitta3, 1Rheumatology, University of Messina, Messina, Italy, 2Pharmacology, University of Messina, Messina, Italy, 3Internal Medicine, University of Messina, Messina, Italy, 4Medical College of Virginia, Richmond, VA

    Background/Purpose: Simvastatin is best known for its antilipidemic action due to its inhibition of 3-hydroxy-3-methylglutaryl CoenzymeA (HMG CoA) reductase. Inhibition of biological precursors in this pathway also…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology